Literature DB >> 17108288

Borrelia burgdorferi spirochetes that harbor only a portion of the lp28-1 plasmid elicit antibody responses detectable with the C6 test for Lyme disease.

Monica E Embers1, Gary P Wormser, Ira Schwartz, Dale S Martin, Mario T Philipp.   

Abstract

Detection of antibody to C6, a peptide that reproduces the sequence of the sixth invariable region within the central domain of the VlsE protein of Borrelia burgdorferi, is used currently for the serologic diagnosis of Lyme disease in humans. B. burgdorferi isolates taken from infected humans can be categorized into specific genetic subtypes (designated RST1, -2, and -3) by restriction fragment length polymorphisms in the 16S to 23S rRNA spacer sequence. Many of these, usually categorized as RST2, retain only segments of the linear plasmid lp28-1, which encodes VlsE. The VlsE genetic region is retained, but altered expression of this molecule could affect diagnosis by the C6 enzyme-linked immunosorbent assay (ELISA). Serum samples from patients infected with each of the three genotypes and from mice infected with three RST2 isolates were tested with the C6 ELISA. Such isolates elicited marked C6 responses in infected mice. The sensitivity of C6 antibody detection in patients infected with RST2 spirochetes was statistically indistinguishable from detection of RST1 and RST3 infections. These findings demonstrate that diagnosis by C6 ELISA remains effective for infection with all B. burgdorferi genotypes, including those with incomplete lp28-1 plasmids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108288      PMCID: PMC1797709          DOI: 10.1128/CVI.00266-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  34 in total

Review 1.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

2.  Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL.

Authors:  F T Liang; E Aberer; M Cinco; L Gern; C M Hu; Y N Lobet; M Ruscio; P E Voet; V E Weynants; M T Philipp
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

3.  A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis.

Authors:  Mario T Philipp; Gary P Wormser; Adriana R Marques; Susan Bittker; Dale S Martin; John Nowakowski; Leonard G Dally
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

4.  Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.

Authors:  Robert P Smith; Robert T Schoen; Daniel W Rahn; Vijay K Sikand; John Nowakowski; Dennis L Parenti; Mary S Holman; David H Persing; Allen C Steere
Journal:  Ann Intern Med       Date:  2002-03-19       Impact factor: 25.391

5.  Characterisation of Borrelia burgdorferi sensu lato strains isolated from patients with skin manifestations of Lyme borreliosis residing in Slovenia.

Authors:  E Ružić-Sabljić; F Strle; J Cimperman; V Maraspin; S Lotrič-Furlan; D Pleterski-Rigler
Journal:  J Med Microbiol       Date:  2000-01       Impact factor: 2.472

6.  Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.

Authors:  G Wang; C Ojaimi; R Iyer; V Saksenberg; S A McClain; G P Wormser; I Schwartz
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions.

Authors:  Gary P Wormser; Edwin Masters; John Nowakowski; Donna McKenna; Diane Holmgren; Katherine Ma; Lauren Ihde; L Frank Cavaliere; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2005-08-31       Impact factor: 9.079

8.  C-terminal invariable domain of VlsE is immunodominant but its antigenicity is scarcely conserved among strains of Lyme disease spirochetes.

Authors:  F T Liang; L C Bowers; M T Philipp
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE.

Authors:  F T Liang; A C Steere; A R Marques; B J Johnson; J N Miller; M T Philipp
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

10.  Characterization of a Borrelia burgdorferi VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay.

Authors:  F T Liang; R H Jacobson; R K Straubinger; A Grooters; M T Philipp
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

View more
  7 in total

1.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

2.  BBK07, a dominant in vivo antigen of Borrelia burgdorferi, is a potential marker for serodiagnosis of Lyme disease.

Authors:  Adam S Coleman; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

3.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

4.  Antigenic Variation in Bacterial Pathogens.

Authors:  Guy H Palmer; Troy Bankhead; H Steven Seifert
Journal:  Microbiol Spectr       Date:  2016-02

5.  Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis.

Authors:  A Marangoni; A Moroni; S Accardo; R Cevenini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-16       Impact factor: 3.267

6.  Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease.

Authors:  Gary P Wormser; Dionysios Liveris; Klára Hanincová; Dustin Brisson; Sara Ludin; Vincent J Stracuzzi; Monica E Embers; Mario T Philipp; Andrew Levin; Maria Aguero-Rosenfeld; Ira Schwartz
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

Review 7.  Laboratory Diagnosis of Lyme Borreliosis.

Authors:  John A Branda; Allen C Steere
Journal:  Clin Microbiol Rev       Date:  2021-01-27       Impact factor: 26.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.